Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission
Acute Myeloid Leukemia
DRUG: IPH2102 at 0.1 mg/kg|DRUG: IPH2102 at 1 mg/kg|DRUG: Placebo (normal saline solution)
Leukemia-Free Survival, from date of randomization until the date of first documented relapse, assessed up to 48 months
Number of Participants With Adverse Events, Number of Participants with Adverse Events based on full physical examination each treatment visit and collection of AEs, from the time of patient signing the consent form until 28 days after the last administration, or until the patient's last study visit, up to 24 months
Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission